(UroToday.com) Renal cell carcinoma (RCC) accounts for ~80%‒90% of all kidney cancers worldwide, with metastatic RCC (mRCC) portending a poor prognosis with a historical 5-year relative survival of 13%. The mRCC treatment landscape is rapidly changing with the approval of new therapies, which has recently been broadened by the FDA approvals of immunotherapy monotherapy in November 2015, dual immunotherapy in April 2018, and more recently immunotherapy-TKI combinations in April 2019. Despite the expanding number of available immunotherapy-based mRCC treatment options, data on the impact of immunotherapy approval on real-world treatment patterns and sequencing are limited. At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Saby George and colleagues presented results of their study investigating the characteristics, treatment patterns, and sequencing for mRCC patients in the real-world setting (December 2015‒May 2020) and in a subgroup analysis of post-dual immunotherapy approval in the United States (April 2018‒May 2020).